Numerous approaches to inhibit PCSK9 have been developed for the treatment of hypercholesterolemia, including anti-PCSK9 monoclonal antibodies24,25, small peptide inhibitors of PCSK926,27, and small interfering RNA28,29. Here, PCSK9 is linked to familial hypercholesterolemia.